Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology
— Partnership leverages Alloy’s high velocity antibody discovery offering to accelerate Normunity’s novel precision immuno-oncology pipeline — BOSTON, MA; November 17, 2022—Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing. The collaboration will support the […]
Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities
— Following a successful expansion from antibodies into T-cell receptors and genetic medicines, Alloy will broaden its pre-competitive discovery technology and discovery services to enable innovative new therapeutic formats — BOSTON, MA; October 03, 2022—Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala […]
Alloy Therapeutics Hires People Executive Trier Bryant as President of Venture Studio, 82VS
—Trier will lead operations and strategy of people-focused venture studio, supporting ecosystem of scientific entrepreneurs— BOSTON, MA; September 07, 2022–Alloy Therapeutics, a biotechnology ecosystem company, welcomes Trier Bryant as President of 82VS, Alloy’s affiliated venture studio. Trier is a strategic executive leader with distinctive tech, Wall Street, and military experience spanning 15 years, and brings a […]
Alloy Therapeutics Ecosystem Offerings Go Intracellular Through Collaboration with Sudhir Agrawal in Genetic Medicines
–Through a partnership with antisense pioneer Agrawal’s Arnay Sciences, Alloy strengthens its mission to democratize enabling drug discovery technology for the global scientific community– BOSTON, MA; June 09, 2022–Alloy Therapeutics, a biotechnology ecosystem company, announced a collaboration and licensing agreement with Sudhir Agrawal’s Arnay Sciences to advance new RNA-based drug discovery platforms and novel chemistries spanning […]
Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning
Biotech ecosystem company Alloy Therapeutics leads the round, joined by Uncommon Denominator and Mytide founders BOSTON, March 8th, 2021–Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, has raised $7 million in Series A financing. The round was led by Alloy Therapeutics, a biotechnology ecosystem company, and was joined by Uncommon […]
Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering
The Basel, Switzerland-based deepCDR team and technology will strengthen Alloy’s antibody discovery platform and services for its ecosystem of 100+ global partners Boston, MA, USA and Basel, Switzerland, December 9th, 2021 – Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and […]
Alloy Therapeutics and Echo Investment Capital Create Wheeler Bio to Accelerate the Development of New Antibody Therapeutics
Wheeler Bio is a biomanufacturing company co-founded by Alloy Therapeutics and Echo Investment Capital to accelerate antibody therapeutics from discovery to IND. Operating out of Oklahoma City and Boston, Wheeler integrates cGMP manufacturing with Alloy’s discovery ecosystem to provide emerging biopharma companies a predictable, high-speed path to clinical trials. BOSTON, MA & OKLAHOMA CITY, OK, […]
Vernal Biosciences Launches to Democratize Access to High Quality mRNA Manufacturing
Seed Financing Will Scale Company’s Technology and Business Operations to Serve Clients of All Stages Vernal Biosciences launched with seed financing led by Alloy Therapeutics to democratize access to high-purity mRNA manufacturing for research and clinical-stage programs. Led by mRNA veteran Christian Cobaugh, Vernal provides a scalable manufacturing platform within the Alloy biotechnology ecosystem to […]
Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases
Alloy Therapeutics and Pyxis Oncology launched Voxall Therapeutics, a joint venture focused on developing novel immune-modulating antibody therapies for cancer and autoimmune diseases. The collaboration integrates Alloy’s ATX-Gx™ discovery platform with Pyxis’ target expertise and preclinical capabilities, facilitated by Alloy’s 82VS venture studio. LEXINGTON & CAMBRIDGE, Mass., May 25th, 2021 – Alloy Therapeutics (“Alloy”) and […]
Alloy Therapeutics Raises $75 Million in Series C Financing to Advance Collaborative Biotechnology Ecosystem
Funds to be used to advance platforms and resources used by scientific entrepreneurs to turn ideas into biological medicines.